Company Name: BIOSENSORS INT'L GROUP, LTD.
Research House: OCBC
OCBC Investment Research starts Biosensors (B20.SG) at Buy with $1.30 target price, says Dow Jones.
OCBC says company’s flagship BioMatrix stent remains the only commercialized biodegradable polymer drug-eluting stent available in market, “which highlights the technological expertise of Biosensors”.
Research house notes heart-stent maker also developing new technology called BioFreedom; “initial trials have showed encouraging results and a successful implementation will provide Biosensors with a further competitive edge.”
OCBC forecasts net profit CAGR of 48.1% over FY10-12. Says recent entry of China-based private equity group Hony Capital as major shareholder with 29.47% stake will help company tap burgeoning Chinese healthcare market.
Shares flat at $1.04.
No comments:
Post a Comment